VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa ® agreement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China.
Stefan Schulze, CEO of Vifor Pharma Group comments, “We are delighted to expand VFMCRP’s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China3 and hyperkalemia is one of the most common complications associated with these two conditions. As a result there is a high demand for an effective, proven hyperkalemia treatment. The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa® to patients.”
Oskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, “This agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology. We believe Veltassa® has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VFMCRP.”
Hyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and can be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin-angiotensin-aldosterone system) inhibitors are at particular risk of developing hyperkalemia. As a consequence, RAASi therapy, the cornerstone of treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has around 6,000 employees in China.
Both parties have agreed to not disclose financial terms of the collaboration.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
Approximately 73% of advanced Chronic Kidney Disease (CKD) and 40% of chronic heart failure patients may be at risk of elevated blood potassium levels4. Hyperkalemia can cause abnormal heart rhythms and even sudden death5. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin II receptor/neprilysin inhibitors (ARNI).
Veltassa® is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium.Veltassa® should not replace emergency treatment for life-threatening hyperkalemia. Made in powder form, Veltassa® is mixed with water and taken once a day with or without food. Veltassa® is consisting of smooth, spherical, uniform microbeads too large to be absorbed, thus protecting the gastrointestinal tract. Veltassa® works primarily in the lumen of the colon where potassium concentration is highest, and the residence time of the polymer is the longest. The potassium is then excreted from the body through the normal excretion process.
1 Veltassa® EU SmPC 2019
2 Agarwal R, et al. Lancet 2019;394:1540–50.
3 Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770. Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112–122.
4 Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.
5 Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
Fresenius SE & Co. KGaA
61352 Bad Homburg, Germany
+49 6172 60 82 115
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Closes H.I.G. Europe Capital Partners III at €1.1 Billion24.11.2020 10:00:00 CET | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative asset management firm with $42 billion of equity capital under management, is pleased to announce the closing of its third European Lower Middle Market Fund, H.I.G. Europe Capital Partners III (the “Fund”). The Fund closed with aggregate capital commitments of €1.1 billion, exceeding its target. The Fund will continue the successful strategy of its two predecessor funds, by making private equity investments in lower middle market companies, primarily in Western Europe. Sami Mnaymneh and Tony Tamer, H.I.G. Co-Founders and Co-CEOs, commented: “We are delighted with the continued support from our limited partner base, which reflects their confidence in the capability of our European team and our differentiated investment approach.” Wolfgang Biedermann, Head of H.I.G. Europe Buyouts, added: “The team is excited to build upon H.I.G.’s successful European lower middle market strategy. The current economic environment in Europe leaves us
FERI Group and Target Global Join Forces for New Growth Fund24.11.2020 09:00:00 CET | Press release
The Bad Homburg-based FERI Group is cooperating with Target Global in the management and placement of a new growth fund. The two companies will work together in the selection of target investments and the placement of this new alternative investment fund for growth capital. This cooperation between one of the leading investment houses in the German-speaking region and one of the most active European venture capital investment companies is the first of its kind. The new Target Global Growth Fund offers investment opportunities in selected growth companies to semi-professional and professional investors. The fund will invest in start-ups with strong growth potential that offer digital products and services in typical European industries for large and preferably global markets – mainly market platforms, Fintechs and service software providers. The fund's investment focus is on companies in early and mid growth phases with valuations in excess of EUR 50 million. "The fund opens up new inve
Exclusive Networks Acquires Nuaware to Accelerate Cloud and DevOps Opportunities for Channel and Vendor Partners24.11.2020 09:00:00 CET | Press release
Exclusive Networks today announced the acquisition of Nuaware, a hyper growth, born-in-the-cloud distributor at the bleeding edge of cloud, DevSecOps and containerisation. The move adds immediate global scale and services capability to the Nuaware proposition and portfolio, while enabling Exclusive Networks, its vendors and partner community with a unique skill set for capitalising on immense demand shifts brought about by digital transformation. Jesper Trolle, CEO at Exclusive Networks said: "DevOps tool chains, containers and the emergence of DevSecOps are specialist areas where Nuaware has carved a truly unique niche in distribution. This acquisition puts us where we want to be in this space, giving our partners a readymade on-ramp into new high-growth opportunities. Large vendors being drawn to these markets are seeking turnkey channel solutions, and their established partner ecosystems have technical skills gaps that demand credible support. We can now meet these kinds of challeng
Aker BP and Cognite Pioneer Robotics Deployment Offshore to Transform Oil and Gas Industry with Autonomous Mission24.11.2020 09:00:00 CET | Press release
Cognitea global industrial AI software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world, has partnered with fully-fledged exploration and production company Aker BP to deploy Spot, the quadruped robotic dog, to pioneer the remote controlled offshore mission on the Skarv installation, 210 kilometers offshore in the North Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005292/en/ Cognite Data Fusion powers Spot, the Boston Dynamics quadruped robot dog, as it completes autonomous mission onboard Aker BP Skarv installation in the North Sea (Photo: Business Wire) The effort continues to build upon Aker BP and Cognite’s bold digital agenda to transform the industry through digitalization, which will result in improved efficiency, safety, and sustainability offshore. This recent endeavor signals a significant opportunity to transform the oil and gas in
beCloud Selects P.I. Works to Drive Automation of its Nationwide Multi-Operator and Multi-Vendor LTE Network24.11.2020 06:00:00 CET | Press release
beCloud, Belarus’ telecommunications infrastructure and service provider, has selected P.I. Works’ cutting-edge network management solutions to drive the automation and proactive monitoring of its multi-operator and multi-vendor 4G network. The deployment has been initiated and will oversee the installation of P.I. Works’ next-generation automation and analytics products, EXA and VantagePM, to enable AI-powered network automation for 24/7 optimization across the operator’s networks. EXA, which runs on the P.I. Works EVO Platform™, will empower beCloud to automatically manage its traffic load, identify cross connection problems without visiting the sites and maximize 4G coverage using existing resources. VantagePM, on the other hand, will enable beCloud to gauge insights into different operator users, monitor individual operator service quality levels, perform rigorous anomaly detection and implement easy-to-use interactive dashboards. To deliver this, P.I. Works utilizes PLMN (network
Global Superstars BTS Team Up With Iconic MapleStory Games in Brand New Collaboration24.11.2020 04:00:00 CET | Press release
Nexon America Inc.: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123006306/en/ MS x BTS Collab Logo (Graphic: Business Wire) WHAT: Today, Nexon announced a collaboration with global record-breaking pop superstars, BTS with the iconic MMORPG IP, MapleStory coming soon. Leading up to the in-game collaboration inMapleStory and MapleStory M, players will be treated to three behind the scenes videos surrounding the MapleStory X BTS collaboration with one new video releasing each week beginning on November 25 via MapleStory’s YouTube channel at youtube.com/MapleStory. The video content will feature BTS sharing their journey growing up with MapleStory through childhood and their fondness for the game. More details on the collaboration will be announced. To stay up to date on the MapleStory X BTS collaboration, visit maplestory.com/maplestoryxbts and follow @maplestory and @playmaplem on Twitter. WHO: MapleStory & MapleStory M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom